case_images: PMC6474052_01
case_images: Photographs of case 1, demonstrating localized moderate chronic periodontitis a before (baseline) and b after 3 months (reassessment) of tofacitinib therapy. Improvements were observed in the gingival index (GI), probing depth (PD), and clinical attachment level (CAL) at the periodontitis-affected site with the black arrow at b (reassessment) compared to those at a (baseline), although the supragingival bacterial plaque level as defined by the plaque control record (PCR) was relatively unchanged (baseline to reassessment: 2 to 0 for GI; 4 mm to 2 mm for both PD and CAL)
case_images: 41927_2019_62_Fig1_HTML.jpg
case_images: PMC6474052_01_41927_2019_62_Fig1_HTML.jpg
case_images: Fig1
case_images: Furthermore, the periodontal assessments indicated that the patient had localized moderate chronic periodontitis at baseline according to the criteria of the Centers for Disease Control and Prevention (CDC)/American Academy of Periodontology (AAP) (Fig. 1a). Tofacitinib therapy reduced periodontal inflammation as indicated by the mean values of the gingival index (GI), probing depth (PD), and clinical attachment level (CAL), as well as the percentage of sites with bleeding on probing (BOP) and of those with PD and CAL of >=4 mm at reassessment, although the teeth count and supragingival bacterial plaque level as defined by the plaque control record (PCR) were relatively unchanged after tofacitinib therapy (Fig. 1b and Table 2).
case_images: PMC6474052_02